Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 15, Issue 13, 1999, Pages 1169-1179

  Haslett, Patrick A J ^a   Klausner, Jeffrey D ^b   Makonkawkeyoon, Sanit ^c   Moreira, Andre ^a   Metatratip, Prasit ^c   Boyle, Brian ^d   Kunachiwa, Warunee ^c   Maneekarn, Niwat ^c   Vongchan, Preeyanat ^c   Corral, Laura G ^a,e   Elbeik, Tarek ^b   Shen, Zhu ^a   Kaplan, Gilla ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; LAMIVUDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOMODULATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VIRUS TITRATION;

ADULT; ANTI-HIV AGENTS; CYTOKINES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-2; LAMIVUDINE; LYMPHOCYTE ACTIVATION; MALE; T-LYMPHOCYTES; THALIDOMIDE; VIRAL LOAD; ZIDOVUDINE;

EID: 0033200056     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310269     Document Type: Article

References (39)

1. Cao Y, Ho DD, Todd J, et al.: Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses 1995;11:353-361.
2. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-575. [See comments]
3. Stanley S, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-1230. [See comments]
4. Brichacek B, Swindells S, Janoff EN, Pirruccello S, and Stevenson M: Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococeal vaccine. J Infect Dis 1996;174:1191-1199.
5. Sulkowski MS, Chaisson RE, Karp CL, et al.: The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998; 178:1642-1648.
6. Kinter AL, Poli G, Fox L, Hardy E, and Fauci AS: HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995;154:2448-2459.
7. Margolick JB, Volkman DJ, Folks TM, and Fauci AS: Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J Immunol 1987;138:1719-1723.
8. Osborn L, Kunkel S, and Nabel GJ: Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86:2336-2340.
9. Pomerantz RJ, Feinberg MB, Trono D, and Baltimore D: Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med 1990;172:253-261.
10. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al.: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-257.
11. Bilello JA, Stellrecht K, Drusano GL, and Stein DS: Soluble tumor necrosis factor-alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients. J Infect Dis 1996;173:464-467.
12. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha pro-duction by stimulated human monocytes. J Exp Med 1991;173: 699-703.
13. Sampaio EP, Kaplan G, Miranda A, et al.: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-414.
14. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schauf V, and Kaplan G: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90: 5974-5978.
15. Moreira AL, Corral LG, Ye W, et al.: Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 1997;13:857-863.
16. Haslett PA, Corral LG, Albert M, and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-1892.
17. Jacobson JM, Greenspan JS, Spritzer J, et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487-1493. [See comments]
18. Haslett P, Tramontana J, Burroughs M, Hempstead M, and Kaplan G: Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997;24:1223-1227.
19. Piscitelli SC, Figg WD, Hahn B, et al.: Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1997;41:2797-2799.
20. Stuyver L, Wyseur A, Rombout A, et al.: Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;41:284-291.
21. Trinchieri G: Immunobiology of interleukin-12. Immunol Res 1998;17:269-278.
22. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
23. Richman DD, Grimes JM, and Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990;3:743-746.
24. Larder BA, Kemp SD, and Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-699.
25. Marseille E, Kahn JG, and Saba J: Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 1998;12:939-948.
26. Haslett P, Hempstead M. Seidman C, et al.: The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13:1047-1054.
27. Tramontana JM, Utaipat U, Molloy A, et al.: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-397.
28. Mueller DL, Jenkins MK, and Schwartz RH: Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-480.
29. Linsley PS and Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11: 191-212.
30. Takenaka H, Maruo S, Yamamoto N, et al.: Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4. J Leukocyte Biol 1997;61: 80-87.
31. Kubin M, Chow JM, and Trinchieri G: Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 1994;83:1847-1855.
32. Libraty DH, Airan LE, Uyemura K, et al.: Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J Clin Invest 1997;99:336-341.
33. Harrison TS and Levitz SM: Priming with IFN-gamma restores deficient IL-12 production by peripheral blood mononuclear cells from HIV-seropositive donors. J Immunol 1997;158:459-463.
34. Moller DR, Wysocka M, Greenlee BM, et al.: Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:5157-5161.
35. Kinter AL, Bende SM, Hardy EC, Jackson R, and Fauci AS: Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995;92:10985-10989.
36. Borthwick NJ, Bofill M, Gombert WM, et al.: Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28-T cells. AIDS 1994;8:431-441.
37. Brinchmann JE, Dobloug JH, Heger BH, et al.: Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: Functional and clinical correlations. J Infect Dis 1994;169:730-738.
38. Clerici M, Lucey DR, Berzofsky JA, et al.: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-1724.
39. Chougnet C, Thomas E, Landay AL, et al.: CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients. Eur J Immunol 1998;28:646-656.